Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)

ClinicalTrials.gov ID: NCT00822094

Public ClinicalTrials.gov record NCT00822094. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 4:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The study investigates if CPX-351 will be a) more effective than the standard intensive salvage AML treatment and b) more tolerable than the standard intensive salvage treatment regimens. The study compares the investigational product CPX-351 vs the standard intensive salvage treatment for first relapse AML patients.

Study identification

NCT ID
NCT00822094
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Jazz Pharmaceuticals
Industry
Enrollment
126 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2009
Primary completion
Nov 30, 2011
Completion
Dec 31, 2011
Last update posted
Nov 23, 2017

2009 – 2012

United States locations

U.S. sites
31
U.S. states
18
U.S. cities
26
Facility City State ZIP Site status
Arizona Cancer Center Tucson Arizona 85724
UCLA Los Angeles California 90024
Cedars Sinai Medical Center Los Angeles California 90048
UC Davis Cancer Center Sacramento California 95817
University of Colorado Cancer Center Aurora Colorado 80045
Northwestern University Robert H. Lurie Comprehensive Cancer Center Chicago Illinois 60611
Rush University Medical Center Chicago Illinois 60612
University of Chicago Medical Center Section of Hematology/Oncology Chicago Illinois 60637
St. Francis Cancer Center Beech Grove Indiana 46107
University of Louisville Brown Cancer Center Louisville Kentucky 40202
Maine General Medical Center Harold Alfond Center for Cancer Care Waterville Maine 04901
Johns Hopkins University Baltimore Maryland 21231
St. Louis University Medical Center St Louis Missouri 63101
The Cancer Center, Hackensack University Medical Center Hackensack New Jersey 07601
North Shore LIJ Center for Advanced Medicine Monter Cancer Center Lake Success New York 11042
Weil Cornell Medical Center New York New York 10021
New York Medical College New York New York 10595
Montefiore Medical Center The Bronx New York 10467
Blumenthal Cancer Center/Mecklenburg Medical Group Charlotte North Carolina 28204
Duke Comprehensive Cancer Center Durham North Carolina 27710
Jewish Hospital of Cincinatti Cincinnati Ohio
Oregon Health and Science University Portland Oregon 97239
Oncology and Hematology at Lehigh Valley Bethlehem Pennsylvania 18105
Western Pennsylvania Hospital Pittsburgh Pennsylvania 15224
UTMB Comprehensive Cancer Center Galveston Texas 77555
M.D. Anderson Cancer Center Houston Texas 77030
Joe Arrington Cancer Center Lubbock Texas 79410
Texas Tech University Health Sciences Center Lubbock Texas 79415
Cancer Therapy and Research Center at The University of TX Health Science Center San Antonio Texas 78229
Intermountain LDS Hospital Salt Lake City Utah 84143
Medical College of Wisconsin Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00822094, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 23, 2017 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00822094 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →